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Abstract  
For more than a century, radiotherapy has been an effective treatment for oncologic patients. The Authors report 
a brief history of the radiation therapy and its actual indication for the treatments of cutaneous malignant diseases. 
Introduction 
 
Radiotherapy (RT), also known as radiation 
therapy, is a treatment modality based on the use of 
high energy rays or radioactive substances, to 
damage tumoral cells and to halt their growth and 
division. 
RT, used alone or in association with different 
treatments, has been an effective tool for treating 
cancer for more than 100 years [1].  
Also today, it is an important therapeutic tool 
for the treatment of different kinds of cancer. It is 
estimated that about two-third of all cancer patients 
will receive RT as unique treatment or as a part of the 
more complex therapeutic protocol. 
 
Radiotherapy in the history 
 
Before the advent of ionising particle beams, 
medicine had few options for treating some diseases, 
both malignant and benign in nature. The scenario 
rapidly changed after the discovery of X-rays in 1895 
by Wilhelm Conrad Rцntgen [2]. 
Also before understanding the physical 
properties of X-rays and their biological effects, one 
year later their discovery, X-rays were used by Emil 
Herman Grubbe to treat a patient with breast cancer 
[3]. 
In the same year, Antoine Henri Becquerel 
started to study the phenomenon of radioactivity and 
to research natural sources of radiation. In 1898, 
Maria Sklodowska-Curie and her husband Pierre 
Curie discovered the radium as a source of radiations. 
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Only three years later, Becquerel and Curie reported 
on the physiologic effects of radium rays [4]. 
By the first years of the new century, an 
increased number of studies reported the use of X-
rays and radium in medicine. Skin cancers were the 
most frequent treated, even because of the low 
penetration in the tissue of radiations. In the 1910s, 
Coolidge developed a new device able to emit higher 
energy X-rays, to treat deeper cancers [5]. 
In real, due to the lack of knowledge on the 
properties and mechanism of actions of radiotherapy, 
the effective, beneficial results in the cancers 
treatment were poor in comparison to their side 
effects and physicians started new studies for a better 
understanding of the treatments [6]. 
New radioactive isotopes, type of rays and 
radiation techniques were discovered. Scientists 
began to understand the nature of radiations, their 
modalities of actions and the relationship between 
time and dose of radiations on cell survival. 
Nevertheless, it was only by 1920s, that physicians 
understood how the administration of the total 
radiation dose in fractionated ones was better than a 
singular treatment session, regarding cancers control 
and fewer side effects [7]. 
Another important scientific progress was 
achieved in 1928 when the International Commission 
on Radiological Protection (ICRP) was created to 
address the question of radioprotection [8]. 
Not less important was the introduction of an 
ionising chamber in 1932, which made physicians 
able to measure the radiation dose delivered to the 
first dose unit (Rцntgen unit) [9]. 
The successive period, from 1930 to 1950, 
was characterised by continuos scientifical progress 
to treat patients affected by deep cancers. This era 
(also known as Orthovoltage era) was mainly 
characterised by the use of the radium-based 
interstitial irradiation (brachytherapy) and by the 
development of supervoltage X-ray tubes able to 
deliver energy from 50 kV to 200 kV. The first one 
modality allowed to the operators to treat the tumour, 
without an external beam source, limiting the side 
effects on unaffected tissue. The second one 
conducted to the introduction of the electron beam 
therapy, a useful therapeutic option able to deliver 
higher and variable energies for treating deeper 
tumours [10]. 
The studies, which had been conducted in the 
successive three decades (Megavoltage era), were 
also focused on the development of more and more 
innovative radio-therapeutic devices able to treat 
cancers in the deep tissues. This period saw the 
introduction of the Cobalt teletherapy, producing high-
energy γ-rays [11], and of more potent electron linear 
accelerators (also known as electron linacs) [12], able 
to deliver megavoltage X-rays. The new devices were 
able to deliver a higher dose of energies than the 
previous ones, making possible the treatment of 
deeper tumours with a greater skin sparing. Due to 
the difficulties of managing these sources and the risk 
to cause an excessive radiation in the tissue 
surrounding cancer, innovative multi-field plans of 
irradiations were designed [13]. 
Radiotherapy was becoming a recognised 
medical discipline, and the first radiologist 
associations were being founded. As well as new 
studies were confirming the efficacy of RT in 
improving survival of patients with different types of 
cancers, innovative devices with a computerised 
control were introduced in the medical practice. 
However, a new era in the history of RT was 
starting. The 1970s and 1980s were characterised by 
the introduction of innovative devices delivering proton 
beam. Even if their first clinical use was dated in 1954 
[14], was only by the late Seventies that computer-
assisted accelerator for protons was successfully 
applied to treat a different kind of tumours [15]. 
The major advantage in the use of ion beams 
is its controllability, which allows providing a superior 
tool for cancer therapy and difficult-to-treat benign 
diseases. 
Another important progress in radiotherapy 
was achieved by the end of the 1990s when the 
introduction of more sophisticated computer allowed 
the development of a 3D conformal radiotherapeutic 
device (Stereotactic radiation therapy), able to treat in 
a more efficacy and safer ways the patients [16]. 
The new millennium saw the affirmation of the 
Stereotactic radiation therapy, especially for the 
treatment of metastatic tumors [17], and the 
introduction of the adaptive RT (ART), a special form 
of image-guided radiotherapy (IGRT), that consent of 
replanning and sometimes optimizing the treatment 
technique, during the course of radiotherapy when 
clinically relevant [18]. 
 
 
Types of radiations useful in RT 
 
Radiotherapy is based on the use of two main 
types of radiation: the electromagnetic and the 
particulate ones. The first is represented by the X-rays 
and by the Gamma-rays; the second one by electrons, 
neutrons and protons. 
Radiations may be delivered externally or 
internally. In the first modality, the beam of radiations 
is delivered by a source of radiations, which is 
external to the body; in the second one, a radioactive 
source is placed inside the lesions that must be 
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treated. 
In general, the choice of the treatment, which 
has to be used, depends on the localisation, size and 
type of cancer. 
 
 
Mechanisms of action of radiotherapy 
 
Even if the interaction radiations-tissue 
produces numerous effects (Table 1), radiotherapy 
mainly acts by killing the tumoral cells and halting their 
ability to reproduce [19]. Those events can be the 
result of the direct damage of DNA or other important 
cellular molecules (most commonly described in the 
case of particulate radiations, such as alpha particles, 
protons or electrons), or of an indirect cellular damage 
which occurs after the productions of free radicals 
(e.g. X-rays or Gamma-rays). 
Unfortunately, during radiation therapy, 
normal cells, especially for those which divide 
frequently, may also be damaged and killed. This fact 
may be limited by the focusing the radiation beam on 
the tumour and by fractioning the total dose of 
irradiation so that normal tissue can recover and 
repair itself [20]. 
Table 1: Effects of radiations on the irradiated tissues 
EFFECT RESULTS  
Physics issue, transfer and absorption of energy  
Biophysics ionisation and excitation phenomenon  
Physical-chemical  direct alterations of atoms and molecules or indirect 
damage through the productions of free radical 
Chemical the breaking of bonds, polymerization or 
depolymerization phenomenon  
Biochemical molecular alterations  
Biochemical-biological damage to DNA, RNA, cytoplasm, enzymes  
Biological aberrations of various cellular components, morpho-
functional and metabolic lesions, damage to the genetic 
material 
 
 
 
Radiotherapy in dermatology 
 
Even if RT is often estimated to be an 
obsolete treatment available for a dermatologist, it has 
been used for nearly a century, and today it still 
represents a valid therapeutic tool even because 
innovative and more sophisticated techniques have 
been developed (Table 2) [20]. 
Radiation therapy may be used in 
dermatology as a curative treatment or as a palliative 
one (Table 3). In the first case, it is used to destroy 
the primary tumour or to reduce the risk of malignant 
recurrences after the surgical or chemotherapeutic 
treatment of cancer. In the second case, RT is mainly 
used to alleviate patient’s pain by reducing the 
tumour’s size. 
 
Table 2: Different modalities of radiotherapy available for the 
treatment of dermatological diseases 
TREATMENT TYPE OF RADIATION CLINICAL INDICATIONS 
Low energy superficial 
kilovoltage 
X-ray 
Localised superficial skin 
cancers 
Orthovoltage X-ray X-rays 
Localised superficial skin 
cancers 
High energy 
megavoltage (MV) 
photons 
X-rays 
Rarely used. Skin cancer 
with deep penetration 
Electron Beam Therapy 
(Linac) 
Electrons Large or thick lesions 
Cobalt therapy Gamma-rays 
Like Linac, by which they 
are often replaced 
Brachytherapy 
Radioactive sources (e.g. 
Au, CO, Celsium, 
Iridium…) localised into 
tumour tissues (variable 
energy) 
Tumours localised in 
critical sites 
 
 
Although the clinical indications for RT are 
numerous (Table 4) [1], the treatment is more often 
performed in patients with known melanoma skin 
cancers (NMSC), such as basal cell carcinoma (BCC), 
squamous cell carcinoma (SCC) and Merkel cell 
carcinoma. 
Table 3: Different indications of RT 
NATURE OF RADIOTHERAPY CLINICAL INDICATIONS 
THERAPY OF FIRST LINE 
Lesions on the face; 
Superficial wide lesions; 
Old patients; 
Patients who cannot be treated 
surgically; 
Cases in which surgery may lead to 
important functional damage (e.g. 
ectropion, paralysis of the facial). 
ADJUVANT THERAPY 
Positive/close margins  after surgical 
excision of tumour; 
Patients with positive nodes;   
Patients with perineural invasion.   
PALLIATIVE TREATMENT 
The Late stage of tumours, which could 
not be treated. 
 
 
BCC is the most common type of skin cancer, 
and maybe one of the more common cancer in 
general. Even if malignant, BCC rarely metastasizes. 
Usually, it is treated with a simple excision or with 
Mohs micrographic surgery. Different therapeutic 
approaches include curettage, electrodesiccation, 
laser ablation, cryotherapy or medical therapies (e.g. 
imiquimod, 5-FU).  
Table 4: Main dermatological indications for RT 
BCC  
SCC  
Bowen’s disease   
Erythroplasia  
Angiosarcoma  
Keratoacanthoma  
Melanoma  
Merkel cell carcinoma  
Cutaneous lymphoma   
Kaposi’s sarcoma  
Fibrosarcoma  
 
RT may be considered as a valid therapeutic 
options, especially in patients who cannot be 
surgically operated, in the case of large tumours or 
not well-defined ones, and finally in the case of 
cancers involving critical site (e.g. nose, ear). On the 
other hand, it has been estimated that the use of RT 
after the surgical excision of the primary tumours, is 
another valid therapeutic approach for patients with 
BCC, leading a reduction in the risk of recurrences 
[21-24] (Table 5, Table 6). 
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Table 5: Dose recommendation for BCC and SCC, accordingly 
to the National Comprehensive Cancer Network (NCCN) 
Guidelines version 2.2014 
Tumour diameter 
(cm) 
Dose (Gy) Margins (cm) Schedule of 
sessions 
< 2 64 1.0-1.5 32 (6-6.4 weeks) 
 55  20 (4 weeks) 
 50  15 (3 weeks) 
 35  5 (5 days) 
≥ 2 66 1.5-2.0 33 (6-6.6 weeks) 
 55  20 (4 weeks) 
Postoperative 
adjuvant 
50  20 (4 weeks) 
 60  30 (6 weeks) 
 
SCC is the second most common cutaneous 
cancer, and unlike BCC it is characterised by a 
significant metastatic potential. 
Table 6: X-ray therapies most commonly used in dermatology 
Modality of irradiation Energy  Treatment depth 
Grenz Rays 10-20 kv < 1 mm 
Contact therapy 40-50 kv 1-2 mm 
Short source surface distance 40-50 kv 1-2 mm 
Superfical therapy 50-150 kv > 5 mm 
Orthovoltage therapy 150-300 kv > 5 mm and < 2 cm 
 
 
Also, in this case, the surgical excision or the 
MOHS micrographic surgery represent the gold 
standard treatments. Different approaches include 
curettage, electrodesiccation and cryosurgery. RT 
may be considered as a valid therapeutic option, both 
as primary treatment and as adjuvant therapy for high-
risk tumours [25]. In patients with positive nodes, the 
irradiation may be considered a valid option to their 
surgical dissection. 
Another tumour which benefits of RT is the 
Merkel cell carcinoma (MCC), a neuroendocrine 
carcinoma of the skin, highly deadly. In this case, the 
surgical excision of the primary tumour is 
recommended such as the successive irradiation of 
the same site. In the case of positive nodes, they must 
be irradiated too [26, 27] 
Among the other skin tumours, which may be 
treated with RT, there is the mycosis fungoids, a form 
of cutaneous T-cell lymphoma. In these cases, RT 
may be used as a curative treatment of localised form 
of lymphoma, or as a palliative treatment [28]. 
Also, the primary cutaneous follicle centre cell 
lymphoma (FCCL) and the primary cutaneous 
marginal zone lymphoma (MZL), two types of B cell 
lymphoma, if not surgically treated, may benefit from 
the radiation therapy [1]. 
Finally, there is the Kaposi’s sarcoma. Also, in 
this case, RT may be used as the main treatment, in 
the case of solitary lesions, or as palliative therapy in 
the disseminated forms [20, 29]. 
Particular is the case of melanoma, the most 
malignant skin disease, characterised to have low 
radiosensitivity. In this case, the gold standard 
treatment is represented by surgical excision of the 
lesion. RT may be considered as therapeutic options 
only in few selective cases, such as unresectable 
primary tumours or lentigo malignant. In the other 
cases, RT is often used with the palliative purpose or 
as adjuvant therapy for the nodal and brain 
metastases [30, 31]. 
The latest introduction of carbon ions in RT 
seems to open new prospective in the melanoma 
treatment, even if new studies and researches need to 
be conducted [32]. 
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